Radius Health Inc., a developer of therapies for osteoporosis and women's health, has set the terms for its initial public offering (IPO).
The Cambridge, Massachusetts-based company has launched an IPO of 6.5 million shares, with an estimated pricing between $8.50 and $10.50 apiece.
At the midpoint of the proposed range, Radius Health's will have an initial market capitalization of roughly $283 million. The company expects net proceeds from the offering to be roughly $55.8 million.
Radius has raised a total of $172.5 million from the following investors including:MPM Capital, HealthCare Ventures LLC, Brookside Capital and Oxford Bioscience Partners.
The company expect to use the net proceeds to fund the clinical development of its most advanced product candidates and for other general corporate purposes.
[Related -A Delicate Balance For US Macro Outlook Via Treasury Yields]
Radius Health's only product candidates are BA058, RAD1901 and RAD140, and none of these product candidates is approved by the FDA for sale, the company said in a regulatory filing.
For the 12 months ended December 2011, Radius Health posted a net loss of $42.5 million.
The company plans to list on the Nasdaq under the symbol "RDUS".
Radius Health has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares to cover over-allotments.
UBS and Leerink Swann will be serving as co-lead underwriters.